Across TCGA pan-cancer cohorts, DDX39A Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated DDX39A data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DDX39A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDX39A expression acts as an unfavorable survival marker.
BLCA are the cancer types where DDX39A Mutation most reproducibly stratifies survival.